Oncodesign signed a two-year service contract with sanofi-aventis, under which it will develop and provide the latter with exclusive experimental tumor-derived models for different types of cancer. Philippe Genne, Oncodesign CEO, suggests the the contract represents “a first for a service company, since it is a long-term collaboration that calls for us to supply experimental models to sanofi-aventis.”
Oncodesign says that unlike traditional cancer models derived from cultured cell lines, its technology is based on patient-derived tumor tissue. Oncodesign has previously worked with sanofi-aventis on the CReMEC (creating a resource center for experimental cancer models) program. It was initiated in 2005 as part of the Medicin Paris Region competition pole to develop and characterize experimental models of colon cancer.